BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target

Benzinga Newsdesk www.benzinga.com Positive 74.9%

Neg 0% Neu 0% Pos 74.9%

BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.